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Identification of the first surrogate agonists for the G 
protein-coupled receptor GPR132
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Mohamed A. Shehataa*, Hanna Belcik Christensena*, Vignir Isberga, b, Daniel 
Sejer Pedersena, Andreas Benderb, Hans Bräuner-Osbornea# and David E. 
Gloriama#  
GPR132 is an orphan Class A G protein-coupled receptor. It has been proposed to be activated by protons 
and to regulate apoptosis, atherosclerosis and inflammation, but these results are still preliminary. In the 
current work, we now designed and screened a focused compound library using a ß-arrestin recruitment 
assay, and thereby identified the first disclosed surrogate GPR132 agonist 1 with a potency of 3.4 µM. 
This constitutes the first available pharmacological tool for the in vitro characterization of the orphan 
receptor GPR132. The testing of 32 analogs furthermore identified a number of compounds with lower 
activity - of which six were agonists and two were antagonists - that were used to construct preliminary 
structure-activity relationships. Docking followed by molecular dynamics simulation of compound 1 in a 
structural model of GPR132 displayed the putative interactions for the key ligand functionalities. 
Introduction 
G protein-coupled receptors (GPCRs) constitute the 
largest family of cell surface receptor proteins1. They are 
involved in the regulation of a wide range of 
physiological processes including vision, metabolism, 
neurotransmission and inflammation2, 3, and 
approximately 30% of FDA-approved drugs are thought 
to target GPCRs4, 5. More than 800 different sequences in 
the human genome encode for GPCRs, of which 
approximately 350 sequences encode for non-olfactory 
receptors6. Their involvement in various physiological 
processes has made GPCRs one of the most pursued 
target classes in academia as well as industry. GPR132 
has been ascribed several putative endogenous ligands. In 
2001, lysophosphatidylcholine was proposed7 to be the 
natural agonist but these results were later retracted8, and 
in 2004 it was shown to function as an antagonist9. In 
2005, another lipid derivative, 9-hydroxy-10E, 12Z-
octadecadienoic acid, was presented as an alternative 
endogenous agonist10, but this could not be confirmed in 
another study11. Independent analyses have instead 
provided evidence that GPR132 functions as a sensor for 
extracellular pH9, 12. This is in agreement with a 
phylogenetic analysis that grouped GPR132 with the 
proton-sensing receptors GPR4, GPR65, and GPR6813. 
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Surrogate GPR132 ligands were reported by Invitrogen 
Discovery Sciences and Amgen in 2009, but without 
disclosing their structures11.  The physiological function 
of GPR132 is still unknown, although several hypotheses 
have been presented. Firstly, studies in this direction 
found that GPR132 triggers chemotaxis of monocytic 
phagolytic cells towards apoptotic cell remnants14 and 
promote anti-inflammatory responses in human skin 
epidermal cells and keratocytes by suppressing DNA 
synthesis and freezing specific cell cycle phases15. 
Secondly, GPR132 is expressed on macrophages16, and 
has been suggested to be involved in atherosclerotic 
lesion growth in the aortic tissue and the coronaries17. 
However, later studies display ambiguous results as the 
formation of atherosclerosis lesions was suppressed and 
promoted by knockout and silencing of the GPR132 
gene, respectively18, 19. Finally, over-expression of 
GPR132 has been found to inhibit tyrosine kinases 
involved in the activation of BCR/ABL fusion proteins20, 
which play a key role in the oncogenesis and 
proliferation of some cancers21. 
 
In this article, we now disclose the first surrogate agonist 
for GPR132 with potency in the single micro-molar 
range (Fig. 1, Chart 1). Receptor structure modeling and 
ligand docking studies present the putative molecular 
mechanism of action, which could contribute to future 
structure-based optimization towards in vivo application. 
The description of the first publically available GPR132 
surrogate agonist is an important first step towards the 
pharmacological and physiological characterization of 
the receptor. 
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Figure 1. Pharmacological characterization of the identified GPR132 agonist 1. (A) Representative concentration-response curve of agonist 1 on the human 
GPR132 receptor. The calculated pEC50 value for 1 is 5.46 ± 0.09  (3.4 µM). Counter screening of 1 on the human β2-adrenergic receptor (β2-AR) receptor, alone (B) or 
with isoproterenol (ISO) (C). ISO is a β2-AR agonist and has been used as a positive control for the β2-AR receptor. The calculated pEC50 value for ISO equals 6.97 ± 
0.05. Measurements of luminescence (RLU) in response to receptors activation have been performed in PathHunter β-arrestin recruitment assays, in CHO cell lines 
expressing human GPR132 (A) or β2-AR (B, C). All data represent mean ± SD from one representative out of five (A) or two (B, C) independent experiments 
performed in triplicates. 
 
Materials and Methods 
GPCR-focused compound libraries 
We designed focused GPCR screening libraries based on 
identification of novel privileged structures, which are 
core scaffolds with known activity at multiple diverse 
receptor targets22-24. We fetched all ~62,000 GPCR-
active ligands from ChEMBL ver.1425 and identified ~50 
frequent substructures using Gaston26 that form parts of 
existing ligands for several diverse GPCR targets, e.g. 
small molecule, peptide and lipid receptors. The design 
of focused screening libraries started by querying these 
“privileged structures” against the entire Enamine 
screening compound collection in Instant JChem27. More 
than 50,000 compounds were exported to Schrödinger 
Maestro28, prepared with LigPrep29 and physicochemical 
properties were calculated with QikProp9. Filters were 
applied to remove reactive structural groups and to enrich 
the dataset for compounds with desirable solubility, size 
and interaction features. Specifically the applied filters 
were: molecular weight (3-500), rotatable bonds (2-10), 
hydrogen bond donors and acceptors (0-5 and 0-10, 
respectively, but requiring at least one of either), QlogS 
(>-6), QlogP (<5), FISA (7-330) and number of rings 
(max 5). The remaining compounds were clustered with 
the Maestro script for Canvas similarity and clustering 
and 1-3 representative compounds were handpicked from 
each cluster. The final library consisted of ~1,600 lead- 
and drug-like screening compounds specifically selected 
for likely GPCR-activity.  
 
To allow for library sub-selection based on target binding 
site charge, the overall library was divided into 3 sub-
libraries containing negatively, neutral and positively 
charged compounds, respectively. All compounds were 
purchased from Enamine (Kiev, Ukraine) as 10 µL of 10 
mM solution in 100% frozen DMSO plated on 384 well 
plates. The structure of compound 1 was confirmed by 
1H NMR and HPCL-MS (Chart SI2). 
Pharmacological assaying 
The G protein signaling pathways of many orphan 
GPCRs are still unknown, making second messenger-
based assays unsuitable for screening for orphan receptor 
ligands. Thus, the β-arrestin2 recruitment assay 
(DisoveRx)30 was employed in the screening and the 
subsequent hit validation. Since recruitment of β-
arrestins constitutes a universal “off-switch” for GPCRs, 
assays based on β-arrestins binding to the activated 
receptors should offer the possibility of detecting GPCRs 
activation regardless of the routes of G protein signaling. 
DiscoveRx β-arrestin2 recruitment assays have been used 
previously for identification of endogenous and surrogate 
ligands of orphan GPCRs31, 32.  
 
24 hours before performing the assay, the PathHunter 
eXpress GPR132 or ADRB2 cells were thawed in 9.5 mL 
of Cell Plating Reagent 1 or 0, respectively. 
Subsequently, 20 µL of cell suspension/well was seeded 
in a 384-well plate (Greiner Bio-One) and incubated 
overnight at 37°C and 5% CO2. On the day of assaying, 
the compound libraries were thawed on a plate shaker at 
450 rpm and ligand plates where prepared with 100 µM 
compound solution in ligand buffer (Hank's balanced salt 
solution, 10 mM HEPES, pH 7.4). Subsequently, 5 µL of 
the ligand solution was added to each well of the cell-
containing plate. Plates were sealed and incubated for 90 
min at 37°C, followed by 30 min incubation at RT. For 
antagonist mode screening, cells were pre-incubated for 
30 min at 37°C with the EC80 of 1 (8.5 µM)
33, followed 
by 60 min incubation at 37°C with the tested compound. 
Thereafter, 12.5 µL of PathHunter detection solution 
(DiscoveRx) was added to each well and plates were 
incubated in darkness for 60 min. Chemiluminescence, 
indicated as relative luminescence units, was measured 
with an EnSpire 2300 Multilabel Reader (PerkinElmer, 
Waltham, MA, USA).  
 
Compounds were screened at 20 µM, in single 
measurements, with 1% (v/v) final concentration of 
DMSO. Hits (compounds with the activity greater than 
three times standard deviations of the assay buffer) were 
subsequently retested in concentration-response studies. 
Analogs of 1 were tested in both agonist and antagonist 
mode (in the presence of 8.5 µM of 1) and a cut-off of 
5% and 25%, respectively, was applied to distinguish 
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active compounds in the agonist and antagonist screen 
mode, respectively. The EC80 of agonist for the 
antagonist mode screening was chosen as a compromise 
between a large assay window (to maximize signal to 
noise ratio) and sensitivity to antagonist33, based on the 
assumption that the tested compounds would behave as 
competitive antagonists given their structural similarity 
with compound 1. To increase chances of observing 
competitive antagonism, the ligands were tested in their 
highest soluble concentration (20 µM). 
Curve fitting was performed by non-linear regression using 
the sigmoidal dose-response equation (variable slope) in 
GraphPad Prism 6.0 (GraphPad Software, San Diego, C.A, 
USA). 
GPR132 Homology Modeling 
The crystal structure34 of the inactive human protease-
activated 1 receptor (PAR1; PDB: 3VW7) was selected 
as the main template, using the GPCRdb template 
selection tool35. The resolution of the PAR1 structure is 
2.20Å. The protein sequence similarity between the 
target and template receptor is 64% in the seven trans-
membrane helical (7TM) region. Based on sequence 
length and similarity, a second template, the human 
chemokine receptor 4 (CXCR4) structure (PDB: 
3ODU),36 was used for the part from the second 
extracellular loop (ECL2) spanning between TM5 and 
the cysteine forming the conserved disulfide bridge to 
TM3. To improve the GPR132 structure model for 
subsequent ligand docking, non-conserved amino acids 
within the binding pocket had their rotamers defined 
based on an in-house GPCR position-specific rotamer 
library that contains rotamers extracted from all 
published GPCR crystal structures37. In this manner, the 
rotamers could be fine-tuned for S1x31, L1x35, Y1x39, W2x60, 
I2x64, T3x28, Y5x40, F5x43, Y6x51, H6x52, V6x54, K6x58, L7x30, 
L7x38, and T7x42. The protein sequences of the chimeric 
template and target were aligned with MEGA5.238, using 
the GPCRdb alignments as a reference for the seven 
helices.  
 
Modeller9v1339 was applied to build 500 homology 
models and the best model was selected based on DOPE 
score. The model backbone was assessed by 
Ramachandran40 plots (Fig. SI1) within the 
PROCHECK41 webserver. The GPR132 model was 
prepared with the Schrödinger Protein Preparation 
Wizard42, including an hydrogen optimization at pH 7 of 
the ionizable polar groups using Maestro PROPKA42. 
Ligand Docking and Molecular Visualization 
Compound 1 was docked with Glide43 in the extra 
precision mode, and flexible ligand sampling was 
applied. The partial charges of the ligands were assigned 
by Epik44 using the OPLS_2005 force field. The van der 
Waals radii scaling factor was set to 0.8 and the partial 
charge cutoff to 0.15. Further options were set to allow 
the rotation of hydroxyl hydrogen atoms in the binding 
site, enhance the planarity of conjugated π-systems, and 
to include the Epik state penalties to the scoring 
calculations. Subsequently, QM-Polarized Ligand 
Docking45 (QPLD) was applied. Jaguar46 performed the 
partial charge calculations with the QM estimation level 
set to accurate (6-31G*/LACVP* basis set, B3LYP 
density functional, and “Ultrafine” Self-Consistent Field 
accuracy level). SiteMap47 was used to map the GPR132 
binding cavity,. Residue positions were indexed with the 
GPCRdb scheme48 , which corrects for helical bulges and 
constrictions. 2D structures were drawn in 
MarvinSketch49 and 3D structures were visualized using 
PyMOL50. 
Molecular Dynamics Simulation 
The receptor-ligand complex was minimized using the 
energy minimization tool in MacroModel51 Schrödinger. 
The TNCG (Truncated Newton Conjugate Gradient) 
minimization method was used with maximum iteration 
steps set to 5000, and the convergence gradient to 0.001. 
Desmond52 was employed to conduct a molecular 
dynamics (MD) simulation for 20 ns on the complex in 
the predefined POPC membrane model. Explicit water 
molecules were handled using the simple point charge 
model. Constant temperature and pressure were applied 
at 300 K and 1.01325 bar, respectively.  The system was 
coupled to an isotropic Berendsen thermo- and barostat, 
with relaxation set to 1 and 2 ps respectively. 
 
Results and Discussion 
Identification of the first surrogate GPR132 agonist 
Screening of the GPCR-focused libraries against the 
human GPR132 receptor yielded a hit (1, Chart 1) with 
3.4 µM potency (Fig. 1A). Compound 1 is racemic and 
thus one of the enantiomers may have a higher potency 
than observed for the racemate. To evaluate whether the 
observed increase in luminescence is GPR132-mediated, 
1 was also tested at another class A GPCR, the β2-AR 
receptor. Ligand 1 did not induce β-arrestin recruitment 
in β2-AR, while the positive control isoproterenol (ISO) 
produced a concentration-dependent response with an 
EC50 of approximately 100 nM (Fig. 1B-C). Hence, we 
concluded that the activity of 1 is not unspecific, but 
mediated via GPR132. 
GPR132 Structure Model and Compound 1 Binding Mode 
To achieve a GPR132 model of sufficient quality for 
ligand docking, we found that it was necessary to locally 
replace the main template (the protease-activated 1 
receptor) with alternative templates. The part of the 
second extracellular loop (ECL2) from the conserved 
cysteine (C45x50) to TM5 is crucial as it acts as a lid of the 
binding pocket in many Class A GPCRs, and it often 
forms ligand interactions53. This segment was longer in 
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Chart 1. Chemical structures of the first disclosed GPR132 surrogate agonist 1 and its analogs 2-29. Ag denotes the six analogs 2, 9, 18, 31, 32, and 33 with weak 
agonistic activity. Ant denotes the two analogs 11 and 12 with weak antagonistic activity. 1 marks the three 1-substituted anthraquinone analogs 12, 16, and 29. 2D 
structures were drawn in MarvinSketch49. 
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the protease-activated 1 receptor (10 instead of 7 
residues); thus the human chemokine receptor 4 (also has 
7 residues) was the most suitable template for modeling 
this segment. Furthermore, for binding pocket residues 
not conserved between the protease-activated 1 receptor 
and GPR132, we applied rotamers from the other most 
homologous receptors. In this way, 29 out of 36 (~81%) 
side chains within the GPR132 binding cavity could be 
defined according to a conserved crystal structure 
template. Validation of the GPR132 model in 
PROCHECK41 showed that 93.5% of the residues are 
within the optimal backbone torsion angles and 6.5% are 
near-optimal (Fig. SI1). 
 
The docking pose of ligand 1 displayed close shape 
complementarity with the GPR132 binding pocket and 
good agreement with the receptor hydrophobic and 
hydrogen bonding sites (Fig. SI2A-C). The R- and S-
enantiomers exhibited very similar binding mode. 
However, the hydrophobic binding site matched the 
methyl substituent better for the R-enantiomer, which 
was therefore chosen for the further analyses. Five 
residues displayed hydrogen bond interactions with the 
ligand namely Y1x39, D45x52, H4x57, Y6X51, and K6x58. Both 
Glide and QPLD resulted in identical outcome. To 
evaluate the accuracy of our docking procedure, we re-
docked the ligands in the three most homologous GPCR 
crystal structures; the protease-activated 1 receptor 
(PDB: 3VW7)34, the µ-opioid receptor (PDB:  4DKL)54, 
and the chemokine receptor type 5 (PDB: 4MBS)55 
respectively. The docked ligands showed very similar 
poses as the crystallized with RMSD values of 0.643, 
1.306, and 0.270 Å, respectively (Fig. SI3A-C). 
 
In our molecular dynamics simulation of the 1 – GPR132 
complex, in a membrane and solvent environment, the 
ligand remained in the same binding cavity throughout 
the entire 20 ns simulation (Video SI1), confirming that 
the complex is stable. The observed interactions and their 
durations are summarized in Figure 2. The anthraquinone 
of 1 appeared to be occupying a hydrophobic site 
between TM3-5 that provided π-π aromatic (Residues 
F3x33 and Y5x39) and hydrophobic (Residues I5x35 and 
P4x59) contacts (Fig. 2C). The pyridinyl ring formed a π-π 
interaction with W2x60 and, together with the methylated 
linker; favorable hydrophobic contacts with several 
aliphatic residues could be seen (Fig. 2C). 
 
The linker amide group displayed hydrogen bonding to 
both Y6x51 and a bridging water molecule to D45x52, a 
residue position in the second extracellular loop that 
often forms contact with Class A receptor ligands53. In 
shorter periods of the simulation, the bond with Y6x51 was 
also indirectly formed via a water molecule (Fig. 2). All 
active analogs have this amide, indicating that its 
interactions could contribute to the stabilization of an 
active receptor conformation. The carbonyl oxygen in the 
amide linker also displayed a potential indirect 
interaction to Y5x40 (Fig. 2C). On the other hand, the 
carbonyl oxygen in the propionate group presented 
indirect hydrogen bonding to Y6x51 (Fig. 2C). 
 
The oxygen atom in the 10-position of the anthraquinone 
ring displayed three putative water-mediated hydrogen 
bond interactions bridging K6x58, D5x32, and the backbone 
of L45x54, respectively. The atom also presented a 
potential direct interaction with Y5x40. The simulation 
showed that the most frequent hydrogen bonds were the 
indirect ones to L45x54 and D5x32 via bridging water 
molecules (Fig. 2C). The oxygen in the 9-position 
presented a direct hydrogen bond interaction with H4x57 
or an indirect one with D45x52 (Fig. 2C). The pyridinyl 
ring nitrogen interacted firmly with Y1x39 (Fig. 2). 
Altogether, six of the seven polar ligand atoms displayed 
hydrogen bond interactions, whereof four mainly 
indirectly via water molecules, and two directly to the 
receptor side chains. 
 
Preliminary Structure-Activity Relationships of 
Compound 1 Analogs 
The structures of compound 1 and the 32 tested analogs 
are shown in Chart 1. All active analogs have lower 
potency than 1, and because of their limited solubility, it 
was not possible to produce full concentration-response 
curves and derive EC50/IC50 values. Instead, their 
relatively weak activities are reported in Table 1 at their 
maximum soluble concentration, which was 10 µM or 20 
µM, respectively. Six of the analogs, namely 2, 9, 18, 31, 
32 and 33, display weak agonistic activity with relative 
Emax between 8-18% at the highest soluble concentration 
(10 or 20 µM, Table 1). 
Table 1. Maximal effects1 of the active analogs2 of 1 at PathHunter eXpress CHO-K1 
cells expressing GPR132 
Compound Rel. Emax (%) SEM Conc. (µM) N 
1 100 - - 5 
2 18 2.9 10 3 
9 9 0.1 20 2 
18 14 2.8 10 3 
31 13 1.0 20 3 
32 13 0.2 20 3 
33 8 0.3 20 3 
 
1The relative Emax of tested compounds was calculated by dividing the span of 
compound response by the span of 1 response in the same experiment and on the same 
plate. 2 Compounds with a relative Emax higher than 5 % were considered as agonists. 
Compound 2 is the most similar analog to 1 and also has 
the highest activity of the analogs (relative Emax of 18% 
at 10 µM). It differs by having a terminal pyrimidine on a 
trigonal nitrogen instead of a pyridine on a tetrahedral 
carbon, which is also the chiral center in compound 1. 
Glide docking of compound 2 showed that the hydrogen 
bond to Y1x39 is lost as this compound lacks the pyridine  
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Figure 2. (A) Top and (B) side views of a representative binding pose of compound 1 (Green), obtained from the molecular dynamics simulation. Hydrogen bonds are shown in 
dashed yellow lines representing the pairings between the ligand polar groups and the different receptor residues (Grey). The simulation ligand interactions diagram (C) represents a 
summary of the interactions observed in the simulation obtained from Desmond. All detected hydrogen bond (purple), and aromatic (green) interactions are represented with their 
corresponding percentages. Residue positions are indexed with the GPCRdb scheme48 to correct for bulges and constrictions. 
 
nitrogen in the 4-position (Fig. SI4A). Compounds 3-5 
have a terminal phenyl moiety and in turn lack the 
methyl group, indicating that either a hydrogen bond 
acceptor in the aryl 4-position or a methyl function could 
be beneficial for activity. Compounds 9 and 10 contain a 
terminal meta-and para-methoxy-phenyl, respectively, on 
a linker that is extended by an extra nitrogen or oxygen 
atom, respectively, compared to 1. In our docking, the 
nitrogen in 9 formed a hydrogen bond to the backbone 
carbonyl of C45x50 (forms a disulfide bridge from the 
second extracellular loop to the top of TM3), whereas the 
oxygen in 10 displayed no interaction (Fig. SI4B-C). 
This provides a hypothesis for the activity of 9, as 
opposed to 10. In the final analogs with agonistic 
activity, 31-33, the 1,1-diphenyl group docked into the 
same site as the pyridine moiety, not the anthraquinone 
core, of compound 1 (Fig. SI4D-F). In each compound, 
the proprionate linker showed a hydrogen bond to Y6x51. 
Only compound 32 was still able to display hydrogen 
bonding to K6x58 via the acetamide terminal group (Fig. 
SI4D-F). 
 
Two of the analogs, 11 and 12, display antagonistic 
activity: the inhibition of compound 1 is 39-46% at 20 
µM (Table 2). These two compounds have higher 
similarity to other non-antagonist analogs than to each 
other. Compound 11 is one of five analogs, 7-11, which 
have a linker that is one atom longer than in compound 1. 
Moreover, 11 is unique in that it has the largest terminal 
substituent, an indole, and lacks a preceding polar 
functionality. 12 is one of three 1-substitued 
anthraquinones (12, 16 and 29). Compared to 16 the ring 
of 12 is non-aromatic and positioned on a one atom 
longer linker. Furthermore, varying linker lengths are 
seen among both agonistic and antagonistic analogs; 
compounds 9, 11, 12, and 18 have linkers that are 
between one atom longer and two atoms shorter. 
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Taken together, the testing of commercially available 
analogs has allowed for the derivation of preliminary 
structure-activity relationships, that although limited, can 
serve as a guide for further lead optimization by custom 
synthesis. 
Table 2. Inhibition1 of 1-mediated β-arrestin recruitment in CHO-GPR132 cells 
upon incubation with indicated concentrations of selected2 analogs of 1 
 
Compound Inhibition (%) SEM Conc. (µM) N 
11 46 16 20 2 
12 39 14 20 2 
1The responses have been normalized to ligand buffer (100 % inhibition) and 8.5 µM 
(EC80) of 1 (0 % inhibition). 
2Compounds with more than 25% inhibition were 
considered as antagonists.  
 
Conclusions 
The association of GPR132 with several alternative 
proposed physiological ligands and functions warrants 
the development of tool compounds that can be used to 
characterize this receptor. In this work, we have 
disclosed the first surrogate agonist 1. The analogs tested, 
and the binding modes and structure-activity 
relationships proposed herein, will be valuable for future 
medicinal chemistry optimization of compound 1, as well 
as mutagenesis of interacting receptor residues. 
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